Aardvark Therapeutics, Inc. Common Stock (AARD) vs Immunic, Inc. (IMUX)

A side-by-side comparison of Aardvark Therapeutics, Inc. Common Stock and Immunic, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Aardvark Therapeutics, Inc. Common Stock logo
AARD
Aardvark Therapeutics, Inc. Common Stock
$109M
$4.96HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
Immunic, Inc. logo
IMUX
Immunic, Inc.
$106M
$7.80HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT

Total return — AARD vs IMUX

growth of $100 · dividends reinvested · last 2y
AARD -63.5% (-39.6%/yr)IMUX -15.9% (-8.3%/yr)IMUX compounded faster over this window
50100150Start $1002026$36$84
AARD IMUX

AARD vs IMUX: by the numbers

  • •AARD is the larger company ($109M vs $106M market cap).

Metrics side by side

Valuation

MetricAARDIMUX
P/B ratio1.450.83

Profitability

MetricAARDIMUX
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-93.44%-87.45%
ROIC-97.99%-92.16%

Growth (annualized)

MetricAARDIMUX
Total return CAGR (5Y)N/A-35.70%

Go deeper

Full AARD analysisFull IMUX analysisInteractive comparison tool

Dig into the metrics

Aardvark Therapeutics, Inc. Common Stock ROEImmunic ROEAardvark Therapeutics, Inc. Common Stock operating marginImmunic operating marginAardvark Therapeutics, Inc. Common Stock revenue growthImmunic revenue growthAardvark Therapeutics, Inc. Common Stock free cash flowImmunic free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.